Eugene Hwang MD

Clinical Trials

• Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Start of enrollment: 2010 Sep 07

  ACTIVE_NOT_RECRUITING

  PHASE2

• Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas Start of enrollment: 2011 Jul 01

  Completed

  Phase 2

• Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Start of enrollment: 2014 Dec 08

  Terminated

  Phase 1

• Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Start of enrollment: 2015 Jun 03

  ACTIVE_NOT_RECRUITING

  PHASE1

• HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

  ACTIVE_NOT_RECRUITING

  PHASE4

• Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG Start of enrollment: 2017 Apr 04

  ACTIVE_NOT_RECRUITING

  NA

• Phase I Study of APX005M in Pediatric Central Nervous System Tumors Start of enrollment: 2018 Mar 01

  ACTIVE_NOT_RECRUITING

  PHASE1

• SGT-53 in Children With Recurrent or Progressive CNS Malignancies Start of enrollment: 2022 Jun 01

  Not yet recruiting

  Early Phase 1

• A Phase 1b Study of PTC596 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Start of enrollment: 2018 Aug 01

  ACTIVE_NOT_RECRUITING

  PHASE1

  Roles: Contact, Principal Investigator

• A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion Start of enrollment: 2021 Apr 08

  RECRUITING

  EARLY_PHASE1

• Multi-antigen T Cell Infusion Against Neuro-oncologic Disease Start of enrollment: 2018 Dec 12

  RECRUITING

  PHASE1

  Roles: Contact, Principal Investigator

• MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2023 Apr 10

  RECRUITING

  PHASE2

  Roles: Contact

• PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma Start of enrollment: 2024 Jul 18

  RECRUITING

  PHASE2

  Roles: Principal Investigator, Contact

• ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2022 Dec 16

  RECRUITING

  PHASE2

  Roles: Contact

• A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma Start of enrollment: 2022 Jul 01

  RECRUITING

  PHASE1

  Roles: Contact

• Targeted Pediatric High-Grade Glioma Therapy Start of enrollment: 2024 Aug 02

  RECRUITING

  Roles: Contact

• Study of Ribociclib and Everolimus in HGG and DIPG Start of enrollment: 2024 Aug 22

  RECRUITING

  PHASE2

  Roles: Contact

• Study of Olutasidenib and Temozolomide in HGG

  RECRUITING

  PHASE2

  Roles: Contact

• Lorlatinib for Newly-Diagnosed High-Grade Glioma with ROS or ALK Fusion Start of enrollment: 2025 Jun 01

  NOT_YET_RECRUITING

  EARLY_PHASE1

  Roles: Contact

• Join now to see all